Specialty Drug Management
PBMs and specialty pharmacy companies managing high-cost biologics.
Market snapshot
These figures describe Pharmacy Benefits Management (PBM) (4.9.7), the segment that Specialty Drug Management sits within. They are not figures for Specialty Drug Management on its own.
- Market size
- ~$284B
- Growth
- ~9.9%CAGR (2017–22, nominal)
- Companies
- ~2,467 firms
68.4% of firms have fewer than 20 employees: 1,687 micro-businesses, below most mandates.
- 20–99
- 43456%
- 100–499
- 17522%
- 500+
- 17122%
revenue largely reflects drug-cost pass-through, not value-add.
NAICS 524292. U.S. Census Bureau, 2022 Statistics of U.S. Businesses; U.S. Census Bureau, 2022 Economic Census.
Business model & economics
Revenue model
Management fees, rebates, and spread on drug flows
Key economics
- Revenue per firm
- $114,938,828
- Revenue per employee
- $640,210
- Employees per firm
- 178.3
- Recurring revenue
- High
- EBITDA margin
- Thin on gross flows; concentrated in rebate/spread economics
- Capex intensity
- Low
multi-year benefit-management contracts
Characteristics
- Scale-driven: payroll is only 12% of revenue, so the cost base is assets, not headcount
- Deep strategic-buyer pool: 171 firms exceed 500 employees, so a scaled asset has trade buyers
- Tight oligopoly vertically integrated with insurers.
- At the center of drug-pricing flows.
- Rebate/spread models under intense regulatory scrutiny.
NAICS 524292. U.S. Census Bureau, 2022 Statistics of U.S. Businesses; U.S. Census Bureau, 2022 Economic Census.
M&A deal context
Who’s acquiring
- Integrated payer-PBMs
- Transparent-PBM challengers
- Health-services strategics
What’s driving deals
- Vertical integration with payers and pharmacy.
- Regulatory and reform scrutiny reshaping the model.
- Transparent-PBM challengers entering the market.
Find Specialty Drug Management acquisition targets
Search Acquisera’s index for companies classified under Specialty Drug Management (4.9.7.3) and build a targeted deal pipeline.
Search companies